News US Curbs Compounding of Weight-Loss Drugs The US FDA proposed on April 30, 2026, to exclude key ingredients like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide from the 503B... Franklin NdibeMay 2, 2026